The Global Animal Health Market Showing Growth, CPhI China to Help Veterinary Drug and Feed Enterprises Integrate with the World Market


The market size of the global veterinary drug industry has grown steadily in recent years driven by the sustained growth of global population and its demands for food, with the global veterinary drug market reaching USD 32.18 billion in 2016 and expected to reach USD 40.01 billion by 2023. The animal health markets of China and other developing countries will maintain a high rise with the rise of the demands for animal products. From the perspective of product classification, the new special antimicrobial drugs for animals have broad market prospects, and the proportion of the high-quality vaccines continues to increase, especially the pig and poultry vaccines have big market demands. Therefore, Chinese enterprises are going after scientific and technological innovation, transformation and upgrading, merger and restructuring, and quality improvement. However equal importance is attached to Chinese and international markets: expand product export while consolidating Chinese market.

With the flourishing animal health market, CPhI China 2018 hosted by UBM EMEA and China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) and co-sponsored by Shanghai UBM Sinoexpo International Exhibition Co., Ltd. (UBM Sinoexpo) will launch a new Animal Health & Feed Zone. This will be held at Shanghai New International Expo Centre on June 20-22, 2018, gathering over 100 quality Chinese and overseas manufacturers of veterinary drugs and feed, setting up a one-stop platform for the pharmaceutical industry, and further promoting the health of humans and animals.

Export enterprises are highly enthusiastic about participating in the exhibition, with attending overseas professional buyers
CPhI China, a super-large event of the pharmaceutical industry in Asia, has become the premier platform for Chinese pharmaceutical enterprises to communicate and exchange with overseas buyers. With the constant deepening of the overseas marketing of the exhibition, the 2018 exhibition is expected to gather over 60,000-person-time Chinese and overseas professional buyers, including over 15,000-person-time overseas buyers from 120 countries and regions, to create more business opportunities for enterprises to exploit overseas market. More export-oriented enterprises regard CPhI exhibition as an important strategic channel to exploit overseas market with the increasing of the overseas professional buyers, including many veterinary drug and feed export enterprises. Some forerunners include China Animal Husbandry Group, Hubei Longxiang, Shandong Shengli, Lifecome Biochemistry, Hubei Masteam Bio-tech, Ningxia Taiyixin, and Jinhe Biotechnology. All having participated in the exhibition for consecutive years, and will further expand the stand area in 2018. They are looking forward to greet the professional buyers from all over the world with better products, finer stand layout, and more professional reception. Professional veterinary drug enterprises such as Shanghai Gongyi Veterinary Medicines Plant, and Hebei Veyong will also exhibit at Hall W5 Animal Health & Feed Zone, to present a high-end animal health event to the industry.

Gathering innovative products and information, helping enterprises achieve transformation and development
To meet the demands of the international market for veterinary drugs and keep enterprise vitality, Chinese veterinary drug enterprises are actively transforming towards innovative enterprises. CPhI China exhibitors such as Longxiang Pharmaceutical has independently developed the tilmicosin enteric granules—Longxiang Tilexin which is made from special enteric-coating materials, blocks the contact between drug and taste bud, and greatly improves the drug palatability; the drug releases at a fixed point in the intestinal tract, to avoid its stimulation on stomach, reduce destruction of gastric acid on the drug, and improve the drug bioavailability. Veyong Animal Pharmaceutical, a Chinese high-tech enterprise with some influence in China’s biochemical field and among the first Chinese enterprises with industrial development of imidacloprid, diflubenzuron, and emamectin, will also bring its efficient, economic, and safe innovative products to the exhibition site, to promote the industry development. The host will hold over 80 pharmaceutical meetings and activities on the site concurrently with the exhibition, including the relevant forum of the veterinary drug industry launched for the first time, and will invite experts in the veterinary drug industry, to focus on the veterinary drug export policies, production processes, and other hot topics, to make a super popular zone.